Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SoundHound AI Inc (SOUN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

SoundHound AI IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

SoundHound AI Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? SoundHound AI Inc trades at $6.47 (market cap $2.92B), while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 45.9× SoundHound AI Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.

SOUNVRTX
Market Cap
$2.92B$134.06B
Sector
TechnologyHealth
52-Week High
$21.40$557.96
52-Week Low
$5.70$376.62
Enterprise Value
$2.72B$128.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SoundHound AI Inc

SoundHound AI (SOUN) trades at $6.57, down 2.52% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company demonstrates strong revenue growth with Q2 2026 revenue up 45% year-over-year to $61.9 million, though it remains unprofitable with a -67.45% net income margin. Recent completion of the LivePerson acquisition creates a leading conversational AI platform with projected 2026 revenue of $230-260 million.

While analyst consensus remains bullish with 75% buy ratings and $8.50 price target (29% upside), significant risks include persistent losses, high valuation multiples (P/S 13.57), and negative cash flow projections for 2026. The stock's heavy short interest (nearly 40%) reflects market skepticism about profitability timeline despite strong top-line growth.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.

Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About SoundHound AI Inc

SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.

Read more on SOUN

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX